Welcome to Division of Infectious Diseases

Department of Medicine, Faculty of Medicine

Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society

Member Login
Lost your password?

Journal Session: Aug 9, 2011-Rilpivirine Issue

08/12/2011
By Rongpong

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Rotating Resident: Natapol K.
Fellow: Paisan T.

Rm 117 Internal Medicine Bldg.
09:00-10:00

On this July 16th issue of the Lancet, the results of 2 major phase III RCTs of Rilpivirine (TMC278), the newest NNRTI, in comparison with Efavirenz for ART-naive patients were introduced.

1. the ECHO study group: Jean-Michel Molina, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine
in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238?46.

2. the THRIVE study group: Calvin J Cohen, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229?37.

plus the comment by Schrijvers R, et al.Rilpivirine: a step forward in tailored HIV treatment. Lancet 2011; 378: 201-3.

Everyone is welcome :D

update adobe acrobat

One Response to Journal Session: Aug 9, 2011-Rilpivirine Issue

  1. Rongpong on 09/08/2011 at 07:42

    The 96-week efficacy results of “THRIVE” were presented in IAS conference, that took place in Rome this year.



จุลชีววิทยา